Advaccine Biotech
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Advaccine Biotech - overview
Established
2009
Location
Suzhou, Jiangsu, China
Primary Industry
Biotechnology
About
Based in Suzhou, China, and established in 2009, Advaccine Biotech is a biotechnology company that focuses on vaccine production. The company has merged with SA Biotech (Suzhou) Pte Ltd and established a large-scale vaccine production system in Suzhou. In December 2020, the initiation of phase II clinical trial of pGX9501 was started. Xian Zhu, the founder and president of the company, has served as Executive Vice President, Chief Scientific Officer, and Chief Biologics Officer for multinational companies such as Fidelity Animal Health, Pfizer Animal Health, etc.
In January 2025, Advaccine Biotech closed a series C+ funding. Advaccine Biotech engages in the development and production of new preventive vaccines and therapeutic vaccines, which can prevent and treat diseases caused by excessive immune responses. The vaccine production of the company includes innovative vaccine technologies such as DNA nucleic acid vaccines, recombinant protein vaccines, and new vaccine adjuvants. It is developing COVID-19 DNA vaccine, new respiratory syncytial virus (RSV) pneumonia vaccine, hepatitis B therapeutic vaccine, etc.
The company generates revenue by developing pet vaccines.
Current Investors
Fortune Capital, Star Capital, New Alliance Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.advaccine.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.